Clinical Trial Update: Safety and Efficacy of FAP iCDC in Ischemia Cardiomyopathy [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and early signals of efficacy of FAP iCDC for ischemic cardiomyopathy. The study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Cardiomyopathy

Drugs mentioned

• FAP iCDC

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Ischemic Cardiomyopathy, Cell Therapy | Phase 1 | Status: NOT_YET_RECRUITING